©The Author(s) 2023.
World J Gastrointest Oncol. Nov 15, 2023; 15(11): 1913-1924
Published online Nov 15, 2023. doi: 10.4251/wjgo.v15.i11.1913
Published online Nov 15, 2023. doi: 10.4251/wjgo.v15.i11.1913
Table 2 Treatment delivery and subsequent therapies
| Median | Range | n | % | |
| MMC/capecitabine | 2.0 | 0.5-9.0 | ||
| Cycles administrated | ||||
| Duration of treatment (mo) | 2.8 | 0.5-20.0 | ||
| Patients beginning Tx at full dosage | ||||
| MMC | ||||
| Capecitabine | 114 | 95.8 | ||
| 45 | 37.8 | |||
| Dose reductions | ||||
| MMC | 3 | 2.5 | ||
| Capecitabine | 16 | 13.5 | ||
| Any | 19 | 16.0 | ||
| Dose intensity (median) | ||||
| MMC (mg/m²/wk) | 1.17 | 0.6-1.6 | ||
| Capecitabine (g/m²/wk) | 9.33 | 4.6-11.9 | ||
| Treatment delay (> 3 d) | ||||
| Yes | 22 | 18.5 | ||
| No | 97 | 81.5 | ||
| Reason for discontinuation | ||||
| Progression | 108 | 90.8 | ||
| Toxicity | 6 | 5.0 | ||
| Other/unknown | 5 | 4.2 | ||
| Subsequent therapies | ||||
| Any | 35 | 29.4 | ||
| Oxaliplatin | 12 | 10.1 | ||
| Irinotecan | 8 | 6.7 | ||
| 5-FU | 18 | 15.1 | ||
| Bevacizumab | 3 | 2.5 | ||
| Cetuximab/panitumumab | 6 | 5.0 | ||
| Regorafenib | 5 | 4.2 | ||
| TAS-102 | 5 | 4.2 | ||
| Other/clinical trial | 8 | 6.7 | ||
| None | 84 | 70.6 | ||
- Citation: Mullin G, Sternschuss M, Landman Y, Sulkes A, Brenner B. Mitomycin C and capecitabine: An additional option as an advanced line therapy in patients with metastatic colorectal cancer. World J Gastrointest Oncol 2023; 15(11): 1913-1924
- URL: https://www.wjgnet.com/1948-5204/full/v15/i11/1913.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i11.1913